Analyst interview with Ziccum's CEO on new project and expanding business dialogues

In a Swedish video interview, Ziccum’s CEO Ann Gidner answers questions from analyst Jonathan Furelid on the topic of business dialogues and agreements.

Apart from elaborating on the significance of the recently concluded Feasibility Study Agreement with ReCode Therapeutics, a leader in the booming mRNA field, Ann Gidner also concludes on the successful completion of the first stage of the Big Pharma II Feasibility Study. Furthermore, Ziccum’s CEO underscores the increasing industry-wide interest generated by Ziccum’s technology, LaminarPaceTM, as evidenced by the growing number of leading industry players reaching out to Ziccum.

Please watch the full interview (in Swedish) here: https://youtu.be/-dnOT8oFLHs

Datum 2024-07-02, kl 08:30
Källa MFN
200 kr till alla nya kunder! Just nu får alla nya kunder på Nordnet 200 kronor insatta i fonden Nordnet One Offensiv. Erbjudandet gäller mellan 1:e och 30:e september!
Investeringar i värdepapper och fonder innebär alltid en risk och det är inte säkert att du får tillbaka det investerade kapitalet